Search hospitals > Maryland > Bethesda
National Institutes of Health Clinical Center, 9000 Rockville Pike
Claim this profileBethesda, Maryland 20817
Global Leader in Healthy Subjects
Global Leader in Cancer
Conducts research for Lymphoma
Conducts research for Post-Implantation Syndrome
Conducts research for Adult T-Cell Leukemia/Lymphoma
3382 reported clinical trials
27 medical researchers
Summary
National Institutes of Health Clinical Center, 9000 Rockville Pike is a medical facility located in Bethesda, Maryland. This center is recognized for care of Healthy Subjects, Cancer, Lymphoma, Post-Implantation Syndrome, Adult T-Cell Leukemia/Lymphoma and other specialties. National Institutes of Health Clinical Center, 9000 Rockville Pike is involved with conducting 3,382 clinical trials across 2,588 conditions. There are 27 research doctors associated with this hospital, such as A P. Chen, Nirali N. Shah, John Glod, MD, and Naoko Takebe.Area of expertise
1Healthy Subjects
Global LeaderStage I
Stage II
TSPO
2Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
A P. ChenNational Institutes of Health Clinical Center2 years of reported clinical research
Expert in Cancer
Studies Parotid Gland Cancer
25 reported clinical trials
68 drugs studied
Nirali N. ShahNational Institutes of Health, Clinical Center8 years of reported clinical research
Studies Adult T-Cell Leukemia/Lymphoma
Studies Acute Myeloid Leukemia
12 reported clinical trials
16 drugs studied
John Glod, MDNational Cancer Institute Pediatric Oncology Branch9 years of reported clinical research
Studies Brain Tumor
Studies Soft Tissue Sarcoma
10 reported clinical trials
13 drugs studied
Naoko TakebeNational Institutes of Health Clinical Center8 years of reported clinical research
Studies Cancer
Studies Parotid Gland Cancer
7 reported clinical trials
13 drugs studied
Clinical Trials running at National Institutes of Health Clinical Center, 9000 Rockville Pike
Cancer
Colorectal Cancer
Depression
Colon Cancer
Lymphoma
Aplastic Anemia
Pancreatic Cancer
Ovarian Cancer
Breast cancer
Epilepsy
Vaccines
for Blood Cancer
Background: People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or certain vaccines. Bruton tyrosine kinase inhibitors (BTKis), which are used to treat blood cancers, may also negatively affect a person s response to certain vaccines. Researchers want to learn more about vaccine responses in people with certain types of blood cancers. The findings may help develop better vaccine strategies for people with these cancers. Objective: To learn how well vaccines work in people who have certain types of blood cancers. Eligibility: Adults aged 18 years or older who have chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, or certain non-Hodgkin lymphomas. Design: Participants will get one or more vaccines for illnesses such as COVID-19, hepatitis B, and shingles. They can choose which vaccines they receive. They will give a blood sample before they get each vaccine. Some vaccines require a second dose 3-6 weeks later. Participants may give an optional blood sample with the second vaccine dose. About 4 weeks after they finish each vaccine series, they will give another blood sample. They will have 2-3 study visits per vaccine. Participants may receive a booster dose for some vaccines. The booster dose is optional. They will give another blood sample with the booster dose. Participants will have pregnancy tests, if needed. Participants with CLL who receive BTKis may be asked to pause treatment for up to 7 weeks. Participants may give follow-up blood samples up to 2 times a year for 5 years. These blood samples are optional. Participation will last for up to 5 years after each vaccine series is received.
Recruiting3 awards Phase 421 criteria
Peposertib + Tuvusertib
for Advanced Cancer
This phase I trial tests the safety, side effects and best dose of peposertib (M3814) in combination with tuvusertib (M1774) in treating patients with solid tumors that have spread to other places in the body (advanced). Peposertib and tuvusertib stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruiting1 award Phase 1
Pomalidomide + Nivolumab
for Viral Associated Cancers
Background: Less toxic and more effective treatments are needed for cancers caused by viruses. These cancers include Hodgkin and non-Hodgkin lymphoma, hepatocellular carcinoma, head and neck cancer, nasopharyngeal carcinoma, gastric cancer, anal cancer, cervical cancer, vaginal cancer, vulvar cancer, penile cancer, Merkel cell carcinoma, Kaposi sarcoma, and leiomyosarcoma. Researchers want to see if a combination of drugs can help. Objective: To find a safe dose of pomalidomide plus nivolumab in people with cancers caused by viruses. Eligibility: Adults ages 18 or older who have cancers caused by Epstein Barr virus (EBV), human herpes virus 8/Kaposi sarcoma herpesvirus (HHV8/KSHV), human papilloma virus (HPV), hepatitis B or C virus (HBV/HCV), and Merkel cell polyomavirus (MCPyV) that have not responded to previous treatments or have relapsed, or in adults who do not want to have surgery because of disfigurement or other risks. Adults who have HIV with any CD4 T cell count are eligible. Design: Participants will be screened with blood and urine tests, scans, and heart tests. They will have a physical exam. Their ability to perform normal daily activities will be assessed. They may have a tumor biopsy. Treatment will be given in 28-day cycles. Participants will take pomalidomide as a tablet by mouth for 21 days of each cycle, for up to 24 cycles. They will get nivolumab by intravenous infusion once each cycle. They will take an aspirin each day until 30 days after their last dose of the study drugs. Participants will keep a pill diary. They will bring it to their study visit at the end of each cycle. At these visits, some screening tests will be repeated. Participants with Kaposi sarcoma will have pictures taken of their lesions. Participants will give blood and saliva samples for research. They may have optional anal and/or cervical swabs. They may have optional biopsies. Participants will have a follow-up visit 30 days after they stop taking the study drugs, then every month for 100 days. Some screening tests will be repeated. Then they may by contacted by phone every 3 months for 9 months, and then every 6 months thereafter....
Recruiting1 award Phase 118 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at National Institutes of Health Clinical Center, 9000 Rockville Pike?
Where is National Institutes of Health Clinical Center, 9000 Rockville Pike located?
Who should I call to ask about financial aid or insurance network?
What insurance does National Institutes of Health Clinical Center, 9000 Rockville Pike accept?
What awards or recognition has National Institutes of Health Clinical Center, 9000 Rockville Pike received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.